Response to ibrutinib over time. (A) Median percent change from baseline in the ALC and the sum of the products of lymph node diameters (SPD) in all patients, showing 95% confidence intervals for all patients. (B) Curves for cumulative best response (CR, PR, and PR-L) for all patients (N = 132). Results for TN patients (n = 31) are shown in C and D. Results for R/R patients (n = 101) are shown in E and F.